Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record.

XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial

Open access
Song, Yuanlin, Yao, Chen, Yao, Yongming, Han, Hui, Zhao, Xiaodong, Yu, Kaijiang, Liu, Luyi, Xu, Ying, Liu, Zhongmin, Zhou, Qingshan, Wang, Ying, Ma, Zhuang, Zheng, Youguang, Wu, Dawei, Tang, Zhongzhi, Zhang, Minzhou, Pan, Shuming, Chai, Yanfen, Song, Yan, Zhang, Jian, Pan, Lei, Liu, Yi, Yu, He, Yu, Xuezhong, Zhang, Hong, Wang, Xiaoge, Du, Zhaohui, Wan, Xianyao, Tang, Yijun, Tian, Yingping, Zhu, Yimin, Wang, Hongliang, Yan, Xiaoyan, Liu, Zhi, Zhang, Boli, Zhong, Nanshan, Shang, Hongcai, Bai, Chunxue·2019·Critical Care Medicine

Abstract

Objectives: To investigate whether XueBiJing injection improves clinical outcomes in critically ill patients with severe community-acquired pneumonia. Design: Prospective, randomized, controlled study. Setting: Thirty-three hospitals in China. Patients: A total of 710 adults 18–75 years old with severe community-acquired pneumonia. Interventions: Participants in the XueBiJing group received XueBiJing, 100 mL, q12 hours, and the control group received a visually indistinguishable placebo. Measurements and Main Results: The primary outcome was 8-day improvement in the pneumonia severity index risk rating. Secondary outcomes were 28-day mortality rate, duration of mechanical ventilation and total duration of ICU stay. Improvement in the pneumonia severity index risk rating, from a previously defined endpoint, occurred in 203 (60.78%) participants receiving XueBiJing and in 158 (46.33%) participants receiving placebo (between-group difference [95% CI], 14.4% [6.9–21.8%]; p < 0.001). Fifty-three (15.87%) XueBiJing recipients and 84 (24.63%) placebo recipients (8.8% [2.4–15.2%]; p = 0.006) died within 28 days. XueBiJing administration also decreased the mechanical ventilation time and the total ICU stay duration. The median mechanical ventilation time was 11.0 versus 16.5 days for the XueBiJing and placebo groups, respectively (p = 0.012). The total duration of ICU stay was 12 days for XueBiJing recipients versus 16 days for placebo recipients (p = 0.004). A total of 256 patients experienced adverse events (119 [35.63%] vs 137 [40.18%] in the XueBiJing and placebo groups, respectively [p = 0.235]). Conclusions: In critically ill patients with severe community-acquired pneumonia, XueBiJing injection led to a statistically significant improvement in the primary endpoint of the pneumonia severity index as well a significant improvement in the secondary clinical outcomes of mortality, duration of mechanical ventilation and duration of ICU stay.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ccm.0000000000003842

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 159

Metadata

Authors
Song, Y., Yao, C., Yao, Y., Han, H., Zhao, X., Yu, K., Liu, L., Xu, Y., Liu, Z., Zhou, Q., Wang, Y., Ma, Z., Zheng, Y., Wu, D., Tang, Z., Zhang, M., Pan, S., Chai, Y., Song, Y., Zhang, J., Pan, L., Liu, Y., Yu, H., Yu, X., Zhang, H., Wang, X., Du, Z., Wan, X., Tang, Y., Tian, Y., Zhu, Y., Wang, H., Yan, X., Liu, Z., Zhang, B., Zhong, N., Shang, H., & Bai, C.
Venue
Critical Care Medicine
Published
2019-09
Volume
47
Issue
9
Pages
e735-e743
ISSN
0090-3493 (ISSN-L)
OpenAlex
W2948924403
Cited by
159
References
0
FWCI
15.07
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1097/ccm.0000000000003842
The paper
Song, Y., Yao, C., Yao, Y., Han, H., Zhao, X., Yu, K., Liu, L., Xu, Y., Liu, Z., Zhou, Q., Wang, Y., Ma, Z., Zheng, Y., Wu, D., Tang, Z., Zhang, M., Pan, S., Chai, Y., Song, Y., . . . Bai, C. (2019). XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial. Critical Care Medicine. https://doi.org/10.1097/ccm.0000000000003842

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.